The deal and who's behind it
Ferring Pharmaceuticals, a privately held Swiss maker of medicines for in-vitro fertilization and reproductive care, struck a $1.4 billion agreement to acquire Gameto. The headline value depends on development, regulatory and commercial milestones. Following the close, Gameto co-founder and CEO Dina Turner will serve in an advisory capacity.
Founded in 2020, Gameto maintains sizable hubs in New York and Austin. It has raised $117 million from investors including Overwater Ventures, Insight Partners, RA Capital and Two Sigma Ventures. Co-founder Martin Varsavsky also launched the Prelude Fertility clinic network in North America.
What Fertilo does differently
IVF typically asks patients to self-inject medications in the abdomen for up to two weeks to stimulate the ovaries to produce the maximum number of mature eggs, which are then collected and frozen or fertilized. The regimen can be hard on patients, and some are advised not to undergo it.
Gameto is advancing another route: in-vitro maturation, where eggs are retrieved while still immature and then grown outside the body. Historically, it has not matched IVF on results. Fertilo aims to change that by using stem cells engineered to function as ovarian support cells to improve the odds, while trimming the protocol to one or two injections. Turner said the program is now in Phase 3 with more than 320 patients.
Why Ferring is buying and how it plans to scale
Ferring is wagering that its worldwide network of fertility clinics and pharmaceutical distribution can help bring Fertilo to patients if US regulators sign off. "We have very strong confidence that the FDA will approve it," Chief Executive Officer and Chairman Jean-Frédéric Paulsen said. "That's why we're doing the deal."
Turner said Ferring's track record with new therapies was pivotal, citing the "infrastructure and compliance and sales and education work" needed to properly launch a novel treatment and reach patients and physicians at scale.
Thoughtful investors welcome new tools that help spot subtle opportunities. We're hosting our first ever investor livestream on 11/17 to show you how to use ChatGPT and Claude to invest like a pro, hosted by Briefs Finance CEO Jaspreet Singh. Save your seat.
The growth angle in women's health
Turner and Paulsen describe the US fertility market as early stage: In the US, under 3% of births involve IVF, while in countries such as Denmark, Korea and Spain, more than 10% of births come from medically assisted conception. If Fertilo lowers the burden on patients, they anticipate more patients will give it a shot or use it alongside other treatments. As Paulsen put it, "The market is just enormous in terms of the growth potential in the US, still."
Beyond Fertilo, Gameto has explored additional uses for its engineered support cells, including applications for menopausal women. Those programs are set to be nurtured within Ferring's venture arm and could spin out as a standalone company. More broadly, big pharma's focus on women's health has picked up, aided partly by robust sales of GLP-1 weight-loss medications to women. Eli Lilly & Co. and Novo Nordisk A/S are studying how their therapies affect women across life stages, including during and after menopause, when weight, metabolism and bone health often shift together.
Investor takeaway
If Fertilo clears the FDA, Ferring's clinic reach and distribution could accelerate adoption of in-vitro maturation, broadening the assisted reproduction toolkit and potentially expanding a market that remains small in the US by birth share. Watch for trial milestones, regulatory signals and updates from Lilly and Novo's women's health research as markers for where capital may move next in this space.
Understanding how artificial intelligence can inform your process builds investor confidence. On 11/17, our CEO Jaspreet Singh goes live for our first ever investor livestream on how to use ChatGPT and Claude to invest like a pro. Register to join him.
